Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.083.51%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.02% | 11.43% | 16.52% | 16.18% | 5.31% |
| Total Depreciation and Amortization | 14.15% | 11.07% | 17.18% | 28.58% | 39.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.33% | 55.49% | 91.37% | 76.49% | 21.43% |
| Change in Net Operating Assets | 23.33% | -9.80% | -306.33% | -1,763.89% | -365.25% |
| Cash from Operations | 11.14% | 21.95% | 12.98% | 2.44% | -2.29% |
| Capital Expenditure | -175.01% | -71.76% | 36.97% | 50.34% | 52.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.00% | 100.00% | 75.28% | 75.42% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 176.11% | 115.87% | 132.85% | -141.13% | -185.24% |
| Cash from Investing | 136.49% | 102.05% | 107.37% | 37.90% | -135.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.63% | -61.52% | -12.31% | -13.36% | -38.72% |
| Repurchase of Common Stock | 38.39% | -112.34% | -147.91% | -360.04% | -366.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -36.58% | -63.50% | -14.55% | -15.62% | -40.34% |
| Foreign Exchange rate Adjustments | -116.70% | 220.87% | 114.18% | 80.26% | 163.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.06% | -57.66% | 109.15% | -4.26% | -178.15% |